Inflammatory bowel disease (IBD) Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Inflammatory Bowel Disease (IBD) Therapeutics Market Report is Segmented by Disease Type (Crohn’s Disease and Ulcerative Colitis), Drug Class (TNF Inhibitors, JAK Inhibitors, Aminosalicylates, Corticosteroids, and Others), Route of Administration (Oral and Parenteral), End User (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (in USD) for the Above Segments.

Inflammatory bowel disease (IBD) Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Inflammatory Bowel Disease (IBD) Therapeutics Industry Overview

The inflammatory bowel disease (IBD) therapeutics market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies that are currently dominating the market are Bristol-Myers Squibb Company, AbbVie Inc., Allergan Therapeutics LLC, Bausch Health Companies Inc. (Salix Pharmaceuticals), Rare Disease Therapeutics Inc., Johnson & Johnson Services Inc., Janssen Biotech, Inc., UCB Inc., and others.

Inflammatory Bowel Disease (IBD) Therapeutics Market Leaders

  1. Bristol-Myers Squibb Company

  2. AbbVie Inc.

  3. Takeda Pharmaceutical Company Limited

  4. Johnson & Johnson Services Inc. (Janssen Biotech, Inc.)

  5. Bausch Health Companies Inc. (Salix Pharmaceuticals)

  6. *Disclaimer: Major Players sorted in no particular order
Inflammatory Bowel Disease (IBD) Therapeutics Market Concentration

Inflammatory Bowel Disease (IBD) Therapeutics Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?